Author

Hong Qin

Stony Brook UniversityORCID 0009-0003-1522-3688Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Hong Qin1 paper · Regenerative Immunotherapy & CAR-T Translational Research Program, Department of Cancer Biology, Division of Hematology and Medical Oncology, Department of Internal Medicine, Department of Immunology, Mayo Clinic, MN, USA

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Organism:mouse· 1 Approach:statistical model· 1

Frequent Co-Authors

Brian S. SheridaniD· 1 shared Jingxuan LiuiD· 1 shared Nancy C. ReichiD· 1 shared Stephen D’AmicoiD· 1 shared Varvara KirilloviD· 1 shared Xinyuan LeiiD· 1 shared Zhijuan QiuiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

7 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Brian S. SheridanORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologyEMBO ReportsPeer-reviewedAug 26, 2025

STAT3 Sustains Tumorigenicity Following Mutant KRAS Ablation

Stephen D’Amico, Varvara Kirillov, Jingxuan Liu…·Nancy C. Reich

This study shows that STAT3 sustains tumorigenicity in KRAS-ablated pancreatic cancer cells, highlighting its role in maintaining malignant identity and suggesting it as a therapeutic target.

2 citations

mousebulk RNA-seq

𝕏 PostBluesky